Health and Healthcare

Amgen : AMGN

All Amgen Articles

699 Articles

Jon C. Ogg | Aug 12, 2019 at 12:10 PM EDT

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current…

Chris Lange | Aug 12, 2019 at 8:50 AM EDT

Short Sellers Make a Move on Big Biotechs

The July 31 short interest data has been compared with the previous report, and short interest in most of these…

Chris Lange | Jul 31, 2019 at 10:00 AM EDT

Why Amgen Is Up Despite Falling Product Sales

Amgen shares rose early Wednesday after it released better than expected second-quarter financial results late on Tuesday.

Chris Lange | Jul 25, 2019 at 8:40 AM EDT

Major Biotechs See Rising Tide in Short Interest

The July 15 short interest data has been compared with the previous report, and short interest in most of these…

Chris Lange | Jul 11, 2019 at 9:50 AM EDT

Short Sellers Run for Cover From Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The June 28 short interest data…

Chris Lange | Jun 26, 2019 at 10:05 AM EDT

Big Biotechs Scare Off Short Sellers

The June 14 short interest data has been compared with the previous report, and short interest in most of these…

Chris Lange | Jun 12, 2019 at 8:40 AM EDT

Big Biotechs Have Short Sellers on the Run

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data…

Jon C. Ogg | Jun 4, 2019 at 11:10 AM EDT

Credit Suisse Calls Out Amgen as Its Key Cancer Winner From ASCO

Amgen is the largest of all biotechs now, and it is being deemed an "ASCO winner" for cancer and oncology…

Chris Lange | May 28, 2019 at 8:35 AM EDT

Major Biotechs See a Rising Tide in Short Interest

The May 15 short interest data have been compared with the previous report, and short interest in most of these…

Jon C. Ogg | May 23, 2019 at 11:40 AM EDT

Citigroup Sees Big Upside for 2 of the Largest Biotechs

Despite the wearing down of hepatitis C drugs and the political climate targeting drug prices, this analyst sees stabilization and…

Jon C. Ogg | May 23, 2019 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: AK Steel, Amgen, Booking, Chubb, Chipotle, Expedia, Gilead, Goodyear, Philip Morris, Target, Zscaler and More

The top analyst upgrades, downgrades and initiations seen on Thursday included AK Steel, Amgen, Booking, Chubb, Chipotle Mexican Grill, Expedia,…

Chris Lange | May 21, 2019 at 9:05 AM EDT

Tuesday’s Top Analyst Upgrades and Downgrades: Tesla, Uber, Amgen, Biogen, Gilead, Deckers, Vertex Pharma, KKR and More

24/7 Wall St. reviews dozens of analyst research reports each day of the week to find new ideas for investors…

Chris Lange | May 10, 2019 at 8:55 AM EDT

Short Sellers Back Off Major Biotechs

The April 30 short interest data have been compared with the previous report, and short interest in most of these…

Chris Lange | Apr 26, 2019 at 9:40 AM EDT

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The April 15 short interest data have been compared with the previous report, and short interest moves in these selected…

Jon C. Ogg | Apr 24, 2019 at 12:55 PM EDT

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top…

1 … 12 13 14 15 16 … 47

Amgen : AMGN

All Amgen Articles

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

Short Sellers Make a Move on Big Biotechs

Why Amgen Is Up Despite Falling Product Sales

Major Biotechs See Rising Tide in Short Interest

Short Sellers Run for Cover From Major Biotechs

Big Biotechs Scare Off Short Sellers

Big Biotechs Have Short Sellers on the Run

Credit Suisse Calls Out Amgen as Its Key Cancer Winner From ASCO

Major Biotechs See a Rising Tide in Short Interest

Citigroup Sees Big Upside for 2 of the Largest Biotechs

Top Analyst Upgrades and Downgrades: AK Steel, Amgen, Booking, Chubb, Chipotle, Expedia, Gilead, Goodyear, Philip Morris, Target, Zscaler and More

Tuesday’s Top Analyst Upgrades and Downgrades: Tesla, Uber, Amgen, Biogen, Gilead, Deckers, Vertex Pharma, KKR and More

Short Sellers Back Off Major Biotechs

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Amgen : AMGN

All Amgen Articles

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

Short Sellers Make a Move on Big Biotechs

Why Amgen Is Up Despite Falling Product Sales

Major Biotechs See Rising Tide in Short Interest

Short Sellers Run for Cover From Major Biotechs

Big Biotechs Scare Off Short Sellers

Big Biotechs Have Short Sellers on the Run

Credit Suisse Calls Out Amgen as Its Key Cancer Winner From ASCO

Major Biotechs See a Rising Tide in Short Interest

Citigroup Sees Big Upside for 2 of the Largest Biotechs

Top Analyst Upgrades and Downgrades: AK Steel, Amgen, Booking, Chubb, Chipotle, Expedia, Gilead, Goodyear, Philip Morris, Target, Zscaler and More

Tuesday’s Top Analyst Upgrades and Downgrades: Tesla, Uber, Amgen, Biogen, Gilead, Deckers, Vertex Pharma, KKR and More

Short Sellers Back Off Major Biotechs

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%